KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Nektar Therapeutics (NKTR) over the last 13 years, with Q3 2025 value amounting to $4.8 million.

  • Nektar Therapeutics' Long-Term Investments rose 661.23% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 661.23%. This contributed to the annual value of $13.9 million for FY2024, which is 4629.62% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Long-Term Investments stood at $4.8 million, which was up 661.23% from $5.4 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Long-Term Investments peaked at $96.1 million during Q1 2021, and registered a low of $4.5 million during Q3 2024.
  • For the 5-year period, Nektar Therapeutics' Long-Term Investments averaged around $29.8 million, with its median value being $22.6 million (2023).
  • In the last 5 years, Nektar Therapeutics' Long-Term Investments plummeted by 8444.52% in 2022 and then skyrocketed by 661.23% in 2025.
  • Nektar Therapeutics' Long-Term Investments (Quarter) stood at $64.8 million in 2021, then plummeted by 86.23% to $8.9 million in 2022, then skyrocketed by 189.26% to $25.8 million in 2023, then tumbled by 46.3% to $13.9 million in 2024, then plummeted by 65.12% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $5.4 million for Q2 2025, and $7.8 million during Q1 2025.